Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Drug:  HLA-A2-restricted synthetic glioma antigen peptides vaccine
Find trials that include:  Any drugs shown
Results 1-3 of 3 for your search:
Start Over
Vaccine Therapy and Poly-ICLC in Treating Younger Patients with Recurrent Low-Grade Gliomas that Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 12 months to less than 22 years
Trial IDs: LGG Vaccine Trial, NCI-2016-00644, NCT02358187
HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine and Poly-ICLC in Treating Children with Newly Diagnosed High-Grade Glioma, Brainstem Glioma, or Recurrent Unresectable Low-Grade Glioma
Status: Active
Phase: No phase specified
Type: Treatment
Age: 19 months to 20 years
Trial IDs: Glioma Vaccine, NCI-2016-00993, NCT01130077
HLA-A2 Restricted Peptide Vaccine and Imiquimod in Treating Children with Recurrent Ependymoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 21 years
Trial IDs: Ependymoma Vaccine, NCI-2016-01096, NCT01795313
Start Over